ABERRANT IMMUNOPHENOTYPES IN B-ACUTE LYMPHOBLASTIC LEUKEMIA
(Abstract release date: 05/19/16)
EHA Library. Nurdan Avci D. 06/09/16; 134506; PB1606
Dr. Duygu Nurdan Avci
Contributions
Contributions
Abstract
Abstract: PB1606
Type: Publication Only
Background
Recently immunophenotyping has a critical role for diagnosis and classification of leukemia and lymphoma. Immunophenotyping is used increasingly for identification of some subtypes, treatment follow-up of minimal residual disease (MRD) and even for prognostic purposes. Also, myeloid and T cell aberrant antigen expressions help to distinguish B acute lymphoblastic leukemia (B-ALL) from hematogones.
Aims
The aim of this study was to evaluate myeloid and T cell aberrant expressions in B-ALL patients who had been referred to our flow cytometry center.
Methods
We retrospectively analyzed the flow cytometry data of newly diagnosed 417 B-ALL samples which were collected in our laboratory between the years 2002-2016. We used a large panel of monoclonal antibodies against lymphoid, myeloid and precursors antigens.
Results
Aberrant antigens were detected in 143/417 (34.29%) of B-ALL patients. Expression of myeloid antigens was a common aberrancy in B-ALL. The leukemic lymphoblasts exhibited aberrant expression of 4 myeloid antigens and 5 T-cell antigens. The most frequently expressed antigen was CD33 (74/143), followed by CD13 (57/143), MPO (2/143), and CD11b (1/143). Dual expression of CD13 and CD33 was seen in 24 patients. Expression of T-cell aberrant antigens was observed in only 8 patients. CD2 was positive in 3 patients, CD5 was positive in 2 patients, and CD3, CD7, CD56 were positive separately in 3 patients.
Conclusion
Aberrant antigen expression is important in MRD follow-up, also it is reported to be associated with prognosis and cytogenetic abnormalities. In literature, adult B-ALL cases expressing CD13 and CD33 have been reported to be related to BCR-ABL positivity. MPO aberrant antigen expressions are very rare and BCR-ABL has been reported mostly negative in MPO positive patients. We have detected MPO aberrant antigen expression in 2 patients, none of them has BCR-ABL positivity. Expression of T-cell antigens has rarely been reported in B-ALL, and the significance of this aberrant antigen expression is unclear. Several studies showed that T-cell aberrant expression leads higher relapse risk and it is associated with adverse cytogenetic abnormalities.
Session topic: E-poster
Keyword(s): B cell acute lymphoblastic leukemia, Immunophenotype
Type: Publication Only
Background
Recently immunophenotyping has a critical role for diagnosis and classification of leukemia and lymphoma. Immunophenotyping is used increasingly for identification of some subtypes, treatment follow-up of minimal residual disease (MRD) and even for prognostic purposes. Also, myeloid and T cell aberrant antigen expressions help to distinguish B acute lymphoblastic leukemia (B-ALL) from hematogones.
Aims
The aim of this study was to evaluate myeloid and T cell aberrant expressions in B-ALL patients who had been referred to our flow cytometry center.
Methods
We retrospectively analyzed the flow cytometry data of newly diagnosed 417 B-ALL samples which were collected in our laboratory between the years 2002-2016. We used a large panel of monoclonal antibodies against lymphoid, myeloid and precursors antigens.
Results
Aberrant antigens were detected in 143/417 (34.29%) of B-ALL patients. Expression of myeloid antigens was a common aberrancy in B-ALL. The leukemic lymphoblasts exhibited aberrant expression of 4 myeloid antigens and 5 T-cell antigens. The most frequently expressed antigen was CD33 (74/143), followed by CD13 (57/143), MPO (2/143), and CD11b (1/143). Dual expression of CD13 and CD33 was seen in 24 patients. Expression of T-cell aberrant antigens was observed in only 8 patients. CD2 was positive in 3 patients, CD5 was positive in 2 patients, and CD3, CD7, CD56 were positive separately in 3 patients.
Conclusion
Aberrant antigen expression is important in MRD follow-up, also it is reported to be associated with prognosis and cytogenetic abnormalities. In literature, adult B-ALL cases expressing CD13 and CD33 have been reported to be related to BCR-ABL positivity. MPO aberrant antigen expressions are very rare and BCR-ABL has been reported mostly negative in MPO positive patients. We have detected MPO aberrant antigen expression in 2 patients, none of them has BCR-ABL positivity. Expression of T-cell antigens has rarely been reported in B-ALL, and the significance of this aberrant antigen expression is unclear. Several studies showed that T-cell aberrant expression leads higher relapse risk and it is associated with adverse cytogenetic abnormalities.
Session topic: E-poster
Keyword(s): B cell acute lymphoblastic leukemia, Immunophenotype
Abstract: PB1606
Type: Publication Only
Background
Recently immunophenotyping has a critical role for diagnosis and classification of leukemia and lymphoma. Immunophenotyping is used increasingly for identification of some subtypes, treatment follow-up of minimal residual disease (MRD) and even for prognostic purposes. Also, myeloid and T cell aberrant antigen expressions help to distinguish B acute lymphoblastic leukemia (B-ALL) from hematogones.
Aims
The aim of this study was to evaluate myeloid and T cell aberrant expressions in B-ALL patients who had been referred to our flow cytometry center.
Methods
We retrospectively analyzed the flow cytometry data of newly diagnosed 417 B-ALL samples which were collected in our laboratory between the years 2002-2016. We used a large panel of monoclonal antibodies against lymphoid, myeloid and precursors antigens.
Results
Aberrant antigens were detected in 143/417 (34.29%) of B-ALL patients. Expression of myeloid antigens was a common aberrancy in B-ALL. The leukemic lymphoblasts exhibited aberrant expression of 4 myeloid antigens and 5 T-cell antigens. The most frequently expressed antigen was CD33 (74/143), followed by CD13 (57/143), MPO (2/143), and CD11b (1/143). Dual expression of CD13 and CD33 was seen in 24 patients. Expression of T-cell aberrant antigens was observed in only 8 patients. CD2 was positive in 3 patients, CD5 was positive in 2 patients, and CD3, CD7, CD56 were positive separately in 3 patients.
Conclusion
Aberrant antigen expression is important in MRD follow-up, also it is reported to be associated with prognosis and cytogenetic abnormalities. In literature, adult B-ALL cases expressing CD13 and CD33 have been reported to be related to BCR-ABL positivity. MPO aberrant antigen expressions are very rare and BCR-ABL has been reported mostly negative in MPO positive patients. We have detected MPO aberrant antigen expression in 2 patients, none of them has BCR-ABL positivity. Expression of T-cell antigens has rarely been reported in B-ALL, and the significance of this aberrant antigen expression is unclear. Several studies showed that T-cell aberrant expression leads higher relapse risk and it is associated with adverse cytogenetic abnormalities.
Session topic: E-poster
Keyword(s): B cell acute lymphoblastic leukemia, Immunophenotype
Type: Publication Only
Background
Recently immunophenotyping has a critical role for diagnosis and classification of leukemia and lymphoma. Immunophenotyping is used increasingly for identification of some subtypes, treatment follow-up of minimal residual disease (MRD) and even for prognostic purposes. Also, myeloid and T cell aberrant antigen expressions help to distinguish B acute lymphoblastic leukemia (B-ALL) from hematogones.
Aims
The aim of this study was to evaluate myeloid and T cell aberrant expressions in B-ALL patients who had been referred to our flow cytometry center.
Methods
We retrospectively analyzed the flow cytometry data of newly diagnosed 417 B-ALL samples which were collected in our laboratory between the years 2002-2016. We used a large panel of monoclonal antibodies against lymphoid, myeloid and precursors antigens.
Results
Aberrant antigens were detected in 143/417 (34.29%) of B-ALL patients. Expression of myeloid antigens was a common aberrancy in B-ALL. The leukemic lymphoblasts exhibited aberrant expression of 4 myeloid antigens and 5 T-cell antigens. The most frequently expressed antigen was CD33 (74/143), followed by CD13 (57/143), MPO (2/143), and CD11b (1/143). Dual expression of CD13 and CD33 was seen in 24 patients. Expression of T-cell aberrant antigens was observed in only 8 patients. CD2 was positive in 3 patients, CD5 was positive in 2 patients, and CD3, CD7, CD56 were positive separately in 3 patients.
Conclusion
Aberrant antigen expression is important in MRD follow-up, also it is reported to be associated with prognosis and cytogenetic abnormalities. In literature, adult B-ALL cases expressing CD13 and CD33 have been reported to be related to BCR-ABL positivity. MPO aberrant antigen expressions are very rare and BCR-ABL has been reported mostly negative in MPO positive patients. We have detected MPO aberrant antigen expression in 2 patients, none of them has BCR-ABL positivity. Expression of T-cell antigens has rarely been reported in B-ALL, and the significance of this aberrant antigen expression is unclear. Several studies showed that T-cell aberrant expression leads higher relapse risk and it is associated with adverse cytogenetic abnormalities.
Session topic: E-poster
Keyword(s): B cell acute lymphoblastic leukemia, Immunophenotype
{{ help_message }}
{{filter}}